United States Thyroid Cancer Diagnostics Market

United States Thyroid Cancer Diagnostics Market Size Report – In a Glance

As per the survey report on United States thyroid cancer diagnostics market, the market is expected to foresee a CAGR value of 4.4% during 2025-2035, and further generate a market size of USD 1.6 billion by the end of 2035. In 2025, the market size was value at USD 1.1 billion revenue.

• The United States thyroid cancer diagnostics market’s growth is driven by increasing cases of thyroid cancer and growing demand for advanced diagnostic treatments.
• KDMI analyst’s growth analysis foresees technological innovations in diagnostic tools as the growth drivers for United States thyroid cancer diagnostics market.

United States (U.S) Thyroid Cancer Diagnostics Market Analysis

Thyroid cancer diagnostics refers to the process of physical examination o check neck lumps, blood tests for hormone levels, and a biopsy to confirm cancer. Further tests like ultrasound, CT scans, MRI scans, and radioactive iodine scanning is required to identify the type of cancer and provide proper treatment to patient. The United States thyroid cancer diagnostics market growth is driven by rising incidence of thyroid cancer in the region with growing demand for advanced diagnostics treatments and provide effective care to patients. According to the report by National Cancer Institute, the rate of new cases of thyroid cancer is 13.5 per 100,000 men and women per year and the death rate is 0.5 per 100,000 per men and women per year. The diagnosing rate of thyroid cancer in approximately 1.1% of men and women, in which women are more prone to thyroid cancer. Abbott, Hologic Inc, and GE Healthcare are some of the significant participants in the US thyroid cancer diagnostics market.

United States Thyroid Cancer Diagnostics Market Growth Drivers and Restraints

Growth Drivers

• Rising incidence of thyroid cancer and growing awareness – The increasing prevalence of thyroid cancer in the US is driving the market growth for diagnostics. With the changing lifestyles and increased consumption of iodine intake, radiation exposure, and others have resulted in the rising incidence of thyroid cancer. Also, the increasing public health awareness by government and healthcare institutions by organizing campaigns, have encouraged individuals to have regular health check-ups, leading to more people preferring advanced diagnostic procedures including fine needle aspiration (FNA), imaging scans, and biomarker testing. Advancement in medical sector has made early detection of diseases possible with high-quality tools, which contributes to the overall market growth.
• Technological innovation in diagnostic tools – With the growing adoption of technological innovation in medical sector and thyroid diagnosing segment, has resulted in improvement of diagnostic technologies, which significantly boosts US market. The integration of high-end ultrasound solutions, molecular testing, next-generation sequencing (NGS), and enhanced immunohistochemistry techniques which improves accuracy, reliability, and recovery time of thyroid cancer and patient care. The innovative solutions enhance patient experience and help physicians to provide personalized treatment strategies by implementing AI-driven solutions and make diagnostic process more efficient.

Restraints

• High cost of advanced diagnostic procedures and reimbursement limitations – The United States thyroid cancer diagnostics market faces major restraint due to the high costs associated with advanced diagnostic tools and procedures and limited reimbursement coverage by insurance companies. Advanced diagnostic tools with enhanced accuracy, often comes with expensive treatment procedures that might not be preferred by price-sensitive patients and due to limited reimbursement policies, patient do not prefer advanced treatment solutions, which limits the market growth.

United States Thyroid Cancer Diagnostics Market Segmentation

Our experts at KD Market Insights have segmented the United States thyroid cancer diagnostics market research report as:

United States Thyroid Cancer Diagnostics Market Competitive Landscape

Some of the significant participants who top the United States thyroid cancer diagnostics market share:

• Abbott
• F.Hoffmann-La Roche Ltd
• Thermo Fisher Scientific, Inc
• Siemens Healthcare GmbH
• Bio-Rad Laboratories, Inc
• GE HealthCare
• Hologic, Inc
• Koninklijke Philips N.V
• Toshiba Corporation
• Agilent Technologies, Inc
• Illumina, Inc.